ViGeneron
Caroline Xu is the Co-Founder and CEO of ViGeneron GmbH, a position held since 2019, specializing in Next Generation Gene Therapy. Prior to this role, Caroline Xu served as Global Director of New Products and Portfolio Strategy at Sandoz BioPharmaceuticals from 2015 to 2018, and held various leadership positions within Novartis, including Head of Strategy and Operations for Novartis Oncology Emerging Growth Markets and Global Director New Products in Neurosciences. Caroline Xu's career began at McKinsey & Company as a Senior Management Consultant, followed by a role as a Medical Scientist at Columbia University Medical Center. Academically, Caroline Xu holds an MBA from Cornell Johnson Graduate School of Management, a Ph.D. in Molecular Pharmacology from the Technical University of Munich, a Master's degree in Pharmacology from the Shanghai Institute of Materia Medica, and a B.S. in Life Science from Nanjing University.
This person is not in any teams
ViGeneron
ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vectorplatform, allows superior transduction efficiency and intravitreal, less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in large genes. Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany.